Test Price
2,800 AED✅ Home Collection Available
ATP2A1 Gene Brody Myopathy Genetic Test in UAE | 2,800 AED | DHA-Licensed NGS Analysis
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified Next Generation Sequencing (NGS) workflow for the ATP2A1 gene.
- Premium Logistics: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all Emirates.
- Clinical Guidance: Post-test clinical interpretation by a DHA-licensed Consultant Medical Genetics specialist via telephonic consultation.
- Insurance: Direct billing verification – WhatsApp +971 54 548 8731.
- Price: 2,800 AED inclusive of genetic counselling and comprehensive clinical report.
Test Overview & Methodology
The ATP2A1 Gene Brody Myopathy Genetic Test detects pathogenic mutations in the ATP2A1 gene using targeted Next Generation Sequencing. This molecular analysis empowers clinical geneticists and neurologists to confirm a diagnosis of Brody myopathy, forecast disease progression, and inform family planning through carrier detection. The test covers all coding exons and flanking intronic regions with deep coverage uniformity.
| Feature | Our Test (NGS Panel) | Closest Alternative (Sanger / WES) |
|---|---|---|
| Methodology | Next Generation Sequencing (full gene coding regions) | Sanger sequencing (single exon) or Whole Exome Sequencing |
| Diagnostic Sensitivity | >99.9% for coding regions | Variable; may miss deep intronic variants |
| Reporting Time | 3–4 Weeks | 4–8 Weeks (WES) / 2–4 Weeks (Sanger) |
| Pre-Test Genetic Counselling | Included – pedigree chart and risk assessment | May require separate referral |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I emphasize that this NGS-based test provides definitive molecular confirmation of Brody myopathy, yet results must always be interpreted within the full clinical context. A pathogenic variant in the ATP2A1 gene carries implications for both the patient and at-risk family members. I strongly recommend post-test genetic counselling to discuss inheritance patterns, surveillance for associated complications, and family planning options. No medical decision, particularly regarding medication or surgery, should be made solely on the basis of a genetic report.”
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory & Exclusion Criteria
- Inability to provide informed consent (or legal guardian consent for minors under UAE Child Protection Law, Federal Decree-Law No. 3 of 2016).
- Acute severe illness where phlebotomy may pose a risk; consultation with our medical team is required prior to scheduling.
- This test does not replace emergency clinical care or acute neurological assessment.
🚨 Emergency Red Flags — Seek Immediate Medical Attention
- Sudden severe muscle weakness or inability to walk
- Difficulty breathing or swallowing
- Chest pain, irregular heartbeat, or fainting
Critical Medication Warning
Do not discontinue, adjust, or initiate any prescribed medication without consulting your treating physician. Genetic results alone do not dictate treatment modifications. All therapeutic decisions must be made by your managing clinician based on complete clinical evaluation.
Patient FAQ & Clinical Guidance
1. What is the purpose of the ATP2A1 gene test?
This test identifies pathogenic mutations in the ATP2A1 gene responsible for Brody myopathy to confirm the diagnosis and guide clinical management. Results are interpreted by a Consultant Medical Genetics specialist and may inform physical therapy planning, cardiac surveillance for arrhythmia risk, and carrier testing for family members.
2. How is the sample collected and can I do it from home?
A trained phlebotomist collects 2–3 mL of whole blood in an EDTA tube, or a dried blood spot on an FTA card. VIP mobile phlebotomy and temperature-controlled home collection are available daily from 8 AM to 11 PM across all Emirates. No fasting is required, and the process takes under 10 minutes.
3. What should I expect after I receive my results?
You will receive a detailed molecular report and a 15-minute telephonic clinical guidance session with a Consultant Medical Genetics specialist. If a pathogenic variant is identified, the report will include a personalised risk assessment for family members, recommendations for cardiac and neurological evaluations, and a discussion of reproductive options.
4. Is pre-test genetic counselling mandatory?
Yes. A detailed clinical history and a genetic counselling session are mandatory before testing. A pedigree chart of family members affected by Brody myopathy will be constructed to inform variant interpretation and risk stratification.
5. How long does it take to get the report?
The turnaround time is 3–4 weeks from sample receipt at the laboratory. This allows for full NGS sequencing, bioinformatics analysis, variant classification per ACMG guidelines, and clinical review by the genetics team.
UAE Regulatory & Data Privacy Adherence
- All personal data is processed under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL); genetic data is de-identified and anonymised after clinical reporting.
- Health data usage complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical testing safety and informed consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Minors require documentation of legal guardian consent as mandated by UAE Child Protection Law (Federal Decree-Law No. 3 of 2016).
- Laboratory accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | ATP2A1 Gene Brody Myopathy Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Targeted Next Generation Sequencing (NGS) of ATP2A1 coding exons and flanking intronic regions |
| ICD-10-CM Code | G71.3 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
Support & WhatsApp: +971 54 548 8731 | Email: care@dnalabsuae.ae
Home Collection Hours: 8:00 AM – 11:00 PM, 7 days a week across all Emirates.
Corporate Lab Branding: DNA Labs UAE
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians